Teacher Retirement System of Texas Sells 1,033 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Teacher Retirement System of Texas cut its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 9.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,457 shares of the company’s stock after selling 1,033 shares during the quarter. Teacher Retirement System of Texas’ holdings in Kymera Therapeutics were worth $286,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. KBC Group NV lifted its position in Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company’s stock worth $68,000 after buying an additional 328 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in shares of Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock worth $198,000 after purchasing an additional 406 shares during the last quarter. State of Wyoming bought a new stake in shares of Kymera Therapeutics during the fourth quarter worth $45,000. GF Fund Management CO. LTD. bought a new stake in shares of Kymera Therapeutics during the fourth quarter worth $55,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Kymera Therapeutics by 7.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company’s stock worth $1,163,000 after purchasing an additional 2,011 shares during the last quarter.

Kymera Therapeutics Stock Down 0.4%

Shares of NASDAQ KYMR opened at $46.18 on Friday. The business’s 50 day moving average price is $40.99 and its 200 day moving average price is $36.24. The firm has a market cap of $3.01 billion, a P/E ratio of -14.90 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. Kymera Therapeutics’s revenue for the quarter was up 114.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.69) earnings per share. As a group, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In related news, Director Elena Ridloff sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total value of $553,200.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jeffrey W. Albers sold 6,349 shares of the company’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $311,101.00. The disclosure for this sale can be found here. Insiders have sold 48,349 shares of company stock valued at $2,334,301 over the last quarter. Company insiders own 16.01% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on KYMR. Wells Fargo & Company decreased their target price on Kymera Therapeutics from $57.00 to $53.00 and set an “overweight” rating for the company in a research report on Thursday, June 26th. UBS Group decreased their target price on Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. JPMorgan Chase & Co. lifted their target price on Kymera Therapeutics from $57.00 to $64.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 3rd. The Goldman Sachs Group upgraded Kymera Therapeutics to a “strong-buy” rating in a report on Tuesday. Finally, Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $59.11.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.